See what computational analyses actually reported, with provenance for every claim.Know what the science actually supports before you trust the answer.
Press Enter β΅ to search claims
Explore by Goal
"Science is the great antidote to the poison of enthusiasm and superstition."
Fast takeaways: multi-study methods (mass single-cell atlases, single-nucleus methods, spatial foundation models, and multimodal alignment) are converging but carry recurrent biases (dataset representativeness, cross-study annotation mismatch, limited biological replication, and model-training bias). See key evidence below and visualized multimodal result from H&Enium data.
Primary evidence highlights: TranscriptFormer: cross-species scale (claimed ~112M cells across 12 species) enabling evolutionary generalization ; H&Enium: aligned imaging+spatial transcriptomics yields +16% cell-type classification lift and published cell-type composition breakdown used in the example graph below .
Long Explanation
Best Evidence: Cell Types β Visual Evidence Analysis
Visuals first β condensed, evidence-linked critique below. All claims are explicitly cited.
Source (composition):
Data sources and caveat: TranscriptFormer claims pretraining on up to ~112 million cells across 12 species (preprint; dataset from CZ CELLxGENE/GEO) ; the HPA whole-body integrated map reports 689,601 cells across 31 tissues ; retina diabetic retinopathy atlas: 297,121 retinal cells from 20 donors (preprint) ; DroNc-seq demonstrated 19,550 human and 19,561 mouse nuclei in deep sequencing tests and established the droplet nucleus approach .
Critical appraisal β strengths and recurring limitations
Strength β scale & multimodality: Large-scale integration (TranscriptFormer; HPA whole-body) and multimodal alignment (H&Enium; AIDO.Tissue spatial pretraining) are improving classification and context-awareness across cell types .
Limitation β representativeness and annotation mismatch: Cross-study nomenclature and sampling biases remain key blind spots (ACE tool exists precisely to compare/translate inconsistent annotations in brain studies) .
Limitation β biological replication & experimental controls: Several machine-guided studies (enhancer design, synthetic models) had limited biological replicates for genomic assays (ATAC/ChIP) and in vivo validations, raising reproducibility concerns (see deep enhancer design paper) .
Limitation β model/data bias & transparency: Industry-backed or company-authored generative single-cell platforms (scGenAI) can produce strong accuracy claims but have COI that require careful independent validation (authors hold equity) .
Limitation β cross-species inference: Cross-species atlases reveal conserved and species-specific cell types (e.g., ileum CA7+ cells present in some species but not others), underscoring that cell-type definitions and functions cannot be naively transferred across species .
What would meaningfully change the conclusions?
Independent replication with fully open pipelines and biological replicates for genome-scale assays (ATAC/ChIP) across multiple labs and tissues (would falsify model-overfitting claims) .
Cross-platform, cross-cohort benchmarks where the same raw data are reprocessed by independent groups (would reveal annotation and pipeline sensitivity; ACE is a useful tool here) .
Practical recommendations for researchers using these resources
Always inspect dataset provenance and sample composition before transferring cell-type labels across datasets (use ACE or manual marker cross-checking) .
Prefer models validated with independent biological replicates and across tissue types; for spatial tasks prioritize spatially pretrained models (AIDO.Tissue) that explicitly encode neighbors .
When using generative or alignment models (TranscriptFormer, scGenAI, H&Enium), perform targeted biological validation (marker-level, ATAC/ChIP, in situ) rather than relying solely on model accuracy metrics .
Done / Delivered: visualized H&Enium composition and cross-study scale; critical evidence synthesis with explicit, source-level citations and clear, testable suggestions to falsify or validate claims.
Key citations (selected, with detailed extracts)
Confidence & next steps: The synthesis above is based on the primary extracted evidence provided. Confidence in the overall assessment (that current methods provide useful cell-type maps but share consistent biases) is ~8/10 given: (1) independent strong-method papers exist (DroNc-seq, HPA, cross-species studies, Nature enhancers), (2) many newer generative/alignment claims remain preprints requiring independent replication. To deepen this analysis I can run cross-paper raw-data meta-analyses (marker concordance, cell-type mapping disagreement matrices, and benchmark re-evaluations). Click "Run AI Scientist Analysis" to start an iterative bioinformatics agent to perform that work.
Preparing scripts to compute cross-study cell-type confusion matrices and marker-concordance using published raw matrices (HPA, retina, H&Enium Xenium) and produce publication-ready plots and per-marker stats.
Get emailed when your analysis is done!
We'll email you the results when your analysis is finished.
Hypothesis Graveyard
Hypothesis: Single universal cell-type definition exists across species β falsified by cross-species ileum atlas showing species-specific CA7+ cells and divergent expression modules
Hypothesis: Model accuracy metrics (AUC, percent accuracy) are sufficient evidence of biological truth β undermined by limited biological replication and COI in some studies (e.g., scGenAI, enhancer design replicates), showing that metrics alone do not ensure mechanistic validity
Quick Explanation
Long Explanation
Top Data Sources
ExportMCP
Keep Exploring
Analysis Wizard
Hypothesis Graveyard
Potential Experiments
Discussion
Explore by Goal
Ask a Follow-Up
Key Insight
